|Bid||36.50 x 3000|
|Ask||36.65 x 900|
|Day's range||36.31 - 36.67|
|52-week range||33.26 - 43.18|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||11.69|
|Earnings date||01 Feb 2017 - 06 Feb 2017|
|Forward dividend & yield||2.11 (5.79%)|
|Ex-dividend date||18 Feb 2021|
|1y target est||46.57|
Dr. Shereef Elnahal, University Hospital CEO, Former NJDOH Commissioner, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on coronavirus vaccines.
GlaxoSmithKline (NYSE: GSK), Vir Biotechnology (NASDAQ: VIR), and Eli Lilly (NYSE: LLY) recently reported positive results from a phase 2 study evaluating a combination of Lilly's bamlanivimab with Vir's and Glaxo's VIR-7831 in treating COVID-19. In this Motley Fool Live video, recorded on March 31, 2021, Motley Fool contributors Keith Speights and Brian Orelli examine those results and discuss which of the three stocks is likely to be the biggest winner going forward.
A proposal currently before the World Trade Organization would waive patent rights on COVID-19 vaccines and treatments in an effort to help low-income nations. Several top Democrats appear to support the move, although the Biden administration has yet to state a position publicly. Despite the push, the president may be hesitant to override patents for pharmaceuticals.